Zantrene Protects Mouse Hearts from Chemotherapy Damage
Zantrene Protects Mouse Hearts from Chemotherapy Damage
30 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from our preclinical cardioprotection program in collaboration with researchers from the University of Newcastle (ASX announcement: 28 April 2021)....
Zantrene shows impressive synergy with BRAF & MEK inhibitors in treating melanoma
Zantrene shows impressive synergy with BRAF & MEK inhibitors in treating melanoma
28 June 2022 – Race Oncology Limited (“Race”) is pleased to share the final results from our preclinical melanoma research program in collaboration with the University of Newcastle (ASX announcement: 19 March 2021). This...
Zantrene Improves Cancer Immunotherapy in a Mouse Model of Treatment Resistant Melanoma
Zantrene Improves Cancer Immunotherapy in a Mouse Model of Treatment Resistant Melanoma
22 June 2022 – Race Oncology Limited (“Race”) is pleased to share further interim results from its preclinical melanoma research program (ASX announcement: 19 March 2021). The program’s objective was to explore the use...
Novel preclinical data published in Cancer Research highlighting Zantrene’s potential in colorectal and pancreatic cancers
Novel preclinical data published in Cancer Research highlighting Zantrene’s potential in colorectal and pancreatic cancers
21 June 2022 – Race Oncology Limited (“Race”) is pleased to announce that two peer reviewed research poster abstracts detailing new preclinical data on the anti-cancer uses of Zantrene (also known as bisantrene or...
Race Oncology Announces On-Market Share Buyback
Race Oncology Announces On-Market Share Buyback
09 June 2022 – Race Oncology Limited (“Race”) is pleased to announce the Board has approved an on-market share buyback for up to 4 million Race Oncology ordinary shares over the next 12 months....
Race Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe
Race Expands FTO Targeting Phase 1b/2a Extramedullary AML & MDS Trial to Europe
08 June 2022 – Race Oncology Limited (“Race”) is pleased to announce it is expanding the FTO-targeted BISECT (RAC-006) clinical trial in extramedullary Acute Myeloid Leukaemia (EMD AML) and Myelodysplastic Syndromes (MDS) to include...
Race CMO Dr David Fuller Talks to Proactive about latest Zantrene Trial News
Zantrene AML Trial at Chaim Sheba, Israel Advances to Phase 2
Zantrene AML Trial at Chaim Sheba, Israel Advances to Phase 2
Race Oncology Limited (“Race”) is pleased to announce the dose escalation Phase 1b stage of the relapsed or refractory Acute Myeloid Leukaemia (R/R AML) trial running at the Chaim Sheba Medical Centre, Israel has...
Race Receives Governance Approval for Extramedullary AML & MDS Human Trial
Race Receives Governance Approval for Extramedullary AML & MDS Human Trial
Race Oncology Limited (“Race”) is pleased to announce it has received Research Governance Office (RGO) approval from the Calvary Mater Newcastle Hospital for its open label clinical trial of Zantrene® (bisantrene dihydrochloride) in patients...
